C
ystic fibrosis (CF) is one of the most common inherited diseases among whites. 1 It is caused by mutations in the CF transmembrane conductance regulator (CFTR) gene, which encodes a transmembrane glycoprotein. 2, 3 The CF transmembrane conductance regulator has been shown to function as a cyclic adenosine monophosphate (cAMP)-regulated chloride channel at the apical membrane of epithelial cells. 4, 5 One of the main consequences of mutations in the CFTR gene is a dysfunction of ion channels resulting in elevated sweat chloride concentrations, pancreatic insufficiency, and progressive lung disease. 6 -10 Since the discovery of the gene, a number of studies have been focused on associations between the genotype and phenotype in CF. 11, 12 At the present time, it is well recognized that there is a wide variability in clinical presentations, organ involvement, disease severity, and life expectancy. 13 For many years, elevated sweat chloride levels were the "gold standard" for diagnosis of CF. 14 Abnormal values were assumed for chloride values Ͼ 60 mEq/L, the 60 mEq/L cutoff discriminating between the populations with CF and without CF. 14, 15 However, patients have been reported with characteristic manifestations of CF and chloride levels Ͻ 60 mEq/L. 16, 17 Moreover, in several cases, genetic analyses have documented two mutated alleles in the CFTR gene, and it is likely that such observations will increase in the next years with the identification of more mutations. 18, 19 Some of these mutations will possibly appear to correlate with a phenotype of mild diseases. Sweat chloride test values Ͻ 60 mEq/L can be separated into two groups: a group of values in the intermediate range of 40 to 60 mEq/L (borderline test results), and a group of values Ͻ 40 mEq/L. 20 From the growing number of observations reported in the literature, there is some evidence that patients with borderline test results share more similarities with the CF patients (eg, patients with chloride values Ͼ 60 mEq/L) in terms of clinical presentations and disease progression than the group of patients with chloride values Ͻ 40 mEq/L.
The crucial issue of definition of CF raised by the number of observations that do not fulfill the classical criteria explain the efforts that need to be made to provide more information on both the genotype and the phenotype of patients with chloride levels Ͻ 60 mEq/L. 21 In the present work, we focused on children who were referred to our pulmonary pediatric department for various pulmonary diseases and whose sweat chloride tests were in the intermediate range of 40 to 60 mEq/L. The aim of the study was to analyze the genotype and the phenotypic characteristics of these patients.
Materials and Methods

Patients
All the children referred to the pulmonary pediatric department between 1988 and 1998 for various pulmonary diseases and who had sweat chloride tests on more than two occasions with median values in the range of 40 to 60 mEq/L were included in the study.
Clinical Evaluation
Personal and familial history, mode of presentation, and age at first diagnosis were recorded for each patient. Sweat chloride levels were measured by the standard protocol of Gibson and Cooke. 14 The quantitative pilocarpine iontophoresis tests were performed with measurements of sweat weight and chloride concentrations in duplicate, with sweat specimens being collected concurrently from the right and left arm. A minimum sweat weight of 100 mg was required for analysis. At least four tests were performed for each patient. Height and weight were recorded at each visit, and the weight-to-height ratio representing the actual weight expressed as a percentage of the ideal weight for height was calculated to determine the nutritional status. Pulmonary disease was evaluated by physical examination, chest radiograph, blood gas analysis at rest, and pulmonary function tests. Before 6 years of age, pulmonary function tests included measurements of functional residual capacity, dynamic lung compliance (Cldyn), and total lung resistance. After 6 years of age, FVC and FEV 1 were determined. Results of these tests were expressed as a percentage of the predicted values for height-matched children. 22, 23 Respiratory bacterial infections were evaluated using quantitative sputum cultures, or cultures of tracheal aspirates when sputum samples were not available. Cultures were considered positive when microorganisms were present at a concentration Ͼ 10 6 cfu/mL. Pancreatic status was determined by the fat content in stool samples collected over 3 days. Patients showing normal results (fecal fat Ͻ 5 g/d) and currently not treated by pancreatic enzyme replacement were defined as pancreatic sufficient, and the remaining were defined as pancreatic insufficient. The levels of blood vitamin A and E were also evaluated. 24 
DNA Analysis
Peripheral blood samples were collected from the children and genomic DNA was extracted by standard methods. For each patient, all 27 exons of the CFTR gene were analyzed by denaturing gradient gel electrophoresis with polymerase chain reaction primers, as described previously. 25 Polymerase chain reaction products that displayed an altered behavior in the gel were subsequently sequenced. Mutations were identified by direct DNA sequencing using an automatic DNA sequencer 373A (Applied Biosystems; Foster City, CA). The cryptic splice mutation 3849 ϩ 10 kb C3 T was detected by restriction analysis according to the instruction of Highsmith et al. 18 The 5-thymidine (5T) variant of the intron 8 polythymidine tract was also documented by direct DNA sequencing.
Statistical Analysis
Results of sweat chloride tests were reported as median (range) . Differences between proportions were tested by the 2 statistic. All p values were two-tailed, and probabilities of Ͻ 0.05 were considered significant.
Results
Clinical Characteristics of the Patients at Initial Evaluation
Twenty-four children (13 boys) could be included in the study. Familial history revealed that patient 6 had a brother followed up for classical CF, including positive sweat chloride test values (65 mEq/L), severe lung disease with chronic Pseudomonas aeruginosa colonization, and pancreatic insufficiency. There was no history of meconial ileus in our 24 children. Characteristics of the children when referred to our pulmonary department are given in Table 1 . The mean age of the patients was 4.8 years (range, 6 months to 10 years). The mean sweat chloride level was 48.4 mEq/L (range, 40 to 59 mEq/L). Respiratory symptoms and findings at first evaluation indicated mainly wheezing (eight children), chronic cough (five children) and recurrent bronchitis (seven children). The time elapsed between onset of respiratory symptoms and initial evaluation in the department ranged from 1 month to 5 years (median, 18 months). Results of blood gas analyses performed in 22 children were normal, except for 1 child who had a Pao 2 of 65 mm Hg (patient 15). In this patient, hypoxemia progressively lessened and oxygen was discontinued after 12 days of treatment with IV antibiotics, corticosteroids, and inhaled ␤ 2 -agonist. Growth and nutritional status indicated a low relative body weight index in six children, with values between 79% and 89% (values Ͻ 90%). Pancreatic insufficiency was documented in two patients (patients 6 and 12).
Clinical Characteristics of the Patients During the Follow-up
The duration of follow-up ranged from 0.5 to 10.5 years for 23 children (1 patient was lost to follow-up). Results are summarized in Tables 2, 3 . Only three children (patients 9, 20, and 21) recovered from their 
Molecular Analysis of the CFTR Gene and CF Diagnosis
Of the 24 patients, 12 patients carried one or two mutations in the CFTR gene (Table 4) . One patient carried homozygous ⌬F508, and two patients carried compound heterozygous (⌬F508/3849 ϩ 10 kb C3 T, S1235R/G551D). Patient 3 was heterozygous for the mutations R75X and D1270H; however, the familial analysis revealed that the mutations R75X and D1270H were both carried by the paternal allele. Eight patients were heterozygous for a CFTR mutations previously described in CF patients. It should be pointed out that patient 6, who was heterozygous ⌬F508, had the same genotype identified in his brother, and familial analysis confirmed that the two children carried the same alleles. As 12 of the 24 patients (50%) with intermediate sweat chloride test results carried at least one CFTR mutation, the frequency of CFTR mutations in the studied population was significantly higher than in the general population (4%), with t ϭ 37.5 (p Ͻ 0.001). 8 The 5T allele variant of intron 8 was identified in four patients. Of the four patients, two patients carried a CFTR mutation on one chromosome and the 5T on the other chromosome (patients 5 and 22). Patient 9 carried the 5T allele and the mild mutation S1235R on the same chromosome. The frequency of the 5T allele in the population of patients with intermediate sweat chloride test results was not statistically different from the frequency 
reported in the general population (frequency of the 5T allele in the general population, 5.2%). 26 Based on the results of DNA analysis and according to the consensus statement on the diagnosis of CF, three patients (patients 9, 12, and 24) met the criteria of both respiratory manifestations and identification of two CF mutations. 21 For patient 6, there was a diagnostic dilemma. Although only one mutation has been identified so far and the sweat chloride concentration was 47 mEq/L, a number of characteristic phenotypic features were present, including history of CF in a sibling, chronic pulmonary disease with infection with typical CF pathogens, and pancreatic insufficiency. After many medical discussions, this child was registered in our CF center.
Discussion
In the present study, we focused on the phenotypic manifestations and genotypic analysis of children with intermediate sweat chloride test results. Among the patients referred to our pulmonary pediatric department for various respiratory manifestations over a 10-year period, we were able to identify 24 patients who had sweat chloride tests on more than two occasions with median values in the range of 40 to 60 mEq/L.
Analysis of the genotype included study of the 27 exons of the CFTR gene, as well as the surrounding intronic sequence 3849 ϩ 10 kb C3 T and the 5T allele. Results indicated that 15 (of 48) chromosomes had a known mutation in CFTR gene, with 1 chromosome bearing two mutations (R75X and D1270H). It is interesting to point out that two patients were compound heterozygous (⌬F508/ 3849 ϩ 10 kb C3 T, S1235R/G551D), and one was homozygous ⌬F508. This genotype is usually observed in patients with high values of sweat chloride concentrations.
Our results documenting the presence of various CFTR mutations extend the conclusions of several reports in the literature that have analyzed the levels of sweat chloride tests in different groups of CF patients. The hypothesis that sweat chloride concentrations may be directly reflective of CF transmembrane conductance regulator activity and that different functional classes of CFTR mutations would display differences in epithelial chloride conductance and in sweat chloride values is no longer sustained. In a study reviewing 455 patients who had two identified CF mutations, Wilschanski et al 27 analyzed the concentrations of sweat chloride levels in CF in relation with the different classes of mutations. They found no differences between patients bearing class I mutations (85 patients), class II mutations (294 patients), and class III mutations (48 patients), all of these patients except 1 in each group having a phenotype of pancreatic insufficiency. They also found similar sweat chloride levels in the group of class V mutations (11 patients), with all the patients included in this group having a pancreatic sufficient status. The only statistical difference they could document was in the group of patients bearing class IV mutations. The mean sweat chloride level in this group was 95 mmol/L, compared to 104 mmol/L in the group of ⌬F508/⌬F508 patients. This difference should be interpreted with caution, because of the smaller number of patients in the group of class IV mutations (17 patients). Indeed, one would have expected class IV and class V mutations to give similar sweat chloride concentrations: these classes of mutations produce proteins that reach the apical membrane and generate cAMP-regulated apical membrane chloride current, with the only observed difference being a reduction in the amount of current for class IV mutations and a reduced amount of normal protein for class V mutations. 28 The 60 mEq/L value of sweat chloride concentrations has been used for a long time to discriminate between the populations of patients with CF and without CF. As for the relation between sweat chloride concentration and CF transmembrane conductance regulator activity, the 60 mEq/L cutoff is questionable. Indeed, from several reports in the literature, it is admitted that normal sweat chloride values do not exclude the diagnosis of CF. 18, 19 In the present study, one patient was ⌬F508/⌬F508. Similar observations have already been reported by other investigators for various mutations. Stewart et al 17 described two patients from two families with the compound heterozygotic CF mutations ⌬F508/ 3849 ϩ 10 kb C3 T. Phenotypic description indicated that these patients had a mild expression of the disease with sweat chloride concentrations of 28 mEq/L and 46 mEq/L, respectively. Interestingly, investigation of the siblings of one patient revealed sweat test levels of 49 mEq/L and 45 mEq/L, and sputum culture positive for P aeruginosa. In the population included in the present study, a patient also carried the genotype ⌬F508/3849 ϩ 10 kb C3 T, with a sweat chloride concentration of 50 mEq/L. The 3849 ϩ 10 kb C3 T mutation was identified by Highsmith et al 18 and corresponds to a point mutation in intron 19. This mutation seemed to be associated with milder disease. 29 A report by Augarten et al 30 of sweat chloride concentrations in patients with this mutation indicated various results less or more than 60 mEq/L. Another interesting finding was the result of the 5T. In our study population, the 5T allele was present in four patients. The 5T allele corresponds to a DNA variant of the intron 8 polypyrimidine tract at the branch acceptor site of exon 9. This variant gives rise to a normal transcript and to a transcript with an in-frame deletion of exon 9, leading to a protein without cAMPactivated chloride conductance activity. 26, [31] [32] [33] Kerem et al 26, 32 showed that the 5T allele can be associated with various clinical presentation and sweat chloride levels ranging from normal to elevated.
Several studies have attempted to correlate genotype and phenotype in CFTR mutations. [11] [12] [13] 34, 35 Although it is well admitted that some mutations, such as ⌬F508, are associated with a more severe clinical presentation, expression of pulmonary disease among the patients carrying these mutations varies considerably. The same observation applies to the pancreatic status as well as to the levels of sweat chloride. This extreme variability supports the concept that disease expression may be the result of CFTR mutations in association with additional genetic and/or environmental factors. 6, 36 Hull and Thomson 36 have addressed the question of the contribution of genes other than CFTR to disease severity in a group of CF patients. Based on the current concept of the role of inflammation in CF pathophysiology, they speculated that the proinflammatory cytokine tumor necrosis factor-␣ and the detoxifying enzyme glutathione S-transferase M1 could influence disease severity. Interestingly, they provided data suggesting some relation between alteration in pulmonary function and tumor necrosis factor-␣-308 promoter polymorphism, as well as homozygosity for the null allele of glutathione Stransferase M1.
The report of the consensus conference initiated by the CF Foundation in the United States stated that the criteria for the diagnosis of CF should include the following: (1) one or more characteristic phenotypic features, or a history of CF in a sibling, or positive newborn screening test results; and (2) an elevated sweat chloride concentration by pilocarpine iontophoresis (Ͼ 60 mmol/L) on two or more occasions, or identification of two CF mutations, or demonstration of abnormal nasal epithelial ion transport. 21 According to these criteria, two of our patients fulfilled the two groups of criteria. For one patient, there was a diagnostic dilemma. To follow the recommendations of the authors of the consensus report, it is clear that there is a need to define more precisely the spectrum of CF phenotypic features, as well as to redefine the guidelines for sweat chloride test interpretation. This is sustained by studies indicating a higher incidence of CFTR gene mutation in patients with diffuse bronchiectasis. 37 In addition, the growing number of described mutations and the complexity of exploring CFTR gene expression indicates that the genetic analysis of the CFTR gene for a given patient may never be complete. 38 Stewart et al 17 discussed the value of nasal transepithelial voltage measurements; however, such measurements are not validated in young children. This leads to the key question: How can we progress to confirm the diagnosis of CF? Considering the difficulties in answering this question, several authors 39 suggest introducing the terms of CFTRassociated disease or CFTR-related disease to cover the various expressions of the disease. With similar concern, Farrell and Koscik 20 discussed the levels of sweat chloride concentrations that should be considered as normal. They concluded that any sweat chloride value Ͼ 40 mEq/L had a low probability of being a true-normal and, therefore, that a diagnosis of CF is likely for levels in the range of 40 to 60 mEq/L.
Data reported in the present work provide support to the conclusion of Farrell and Koscik. 20 From the current understanding of the role of CFTR in airway disease, assiduous care and medical follow-up of the patients with intermediate sweat chloride test results should be recommended. These patients should undergo a treatment program according to protocols designed for CF patients, with an aggressive management of pulmonary exacerbations. 40 -44 
